306 related articles for article (PubMed ID: 29939848)
1. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.
Zagelbaum NK; Yandrapalli S; Nabors C; Frishman WH
Cardiol Rev; 2019; 27(1):49-56. PubMed ID: 29939848
[TBL] [Abstract][Full Text] [Related]
2. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
Bilen O; Ballantyne CM
Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
[TBL] [Abstract][Full Text] [Related]
3. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
Burke AC; Telford DE; Huff MW
Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
[TBL] [Abstract][Full Text] [Related]
4. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
5. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Brandts J; Ray KK
Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
[TBL] [Abstract][Full Text] [Related]
6. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
7. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
Paton DM
Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
[TBL] [Abstract][Full Text] [Related]
8. ETC-1002: a future option for lipid disorders?
Nikolic D; Mikhailidis DP; Davidson MH; Rizzo M; Banach M
Atherosclerosis; 2014 Dec; 237(2):705-10. PubMed ID: 25463109
[TBL] [Abstract][Full Text] [Related]
9. Bempedoic acid for the treatment of hypercholesterolemia.
Yang J
Expert Rev Cardiovasc Ther; 2020 Jul; 18(7):373-380. PubMed ID: 32532162
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
[TBL] [Abstract][Full Text] [Related]
11. Evaluating bempedoic acid for the treatment of hyperlipidaemia.
Penson P; McGowan M; Banach M
Expert Opin Investig Drugs; 2017 Feb; 26(2):251-259. PubMed ID: 28064554
[TBL] [Abstract][Full Text] [Related]
12. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).
Agha AM; Jones PH; Ballantyne CM; Virani SS; Nambi V
J Clin Lipidol; 2021; 15(5):649-652. PubMed ID: 34393074
[TBL] [Abstract][Full Text] [Related]
13. Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia.
Schimmenti C; Sucato V; Manzone E; Cancellieri G; Mortillaro F; Novo G; Galassi AR; Venturella F
Coron Artery Dis; 2021 Jun; 32(4):340-344. PubMed ID: 33229935
[TBL] [Abstract][Full Text] [Related]
14. Bempedoic acid (Nexletol) for lowering LDL-cholesterol.
Med Lett Drugs Ther; 2020 Apr; 62(1595):53-55. PubMed ID: 32324179
[No Abstract] [Full Text] [Related]
15. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
[TBL] [Abstract][Full Text] [Related]
16. Mendelian Randomization Study of
Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ
N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797
[TBL] [Abstract][Full Text] [Related]
17. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR
Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432
[TBL] [Abstract][Full Text] [Related]
18. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
Susekov AV; Korol LA; Watts GF
Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Di Minno A; Lupoli R; Calcaterra I; Poggio P; Forte F; Spadarella G; Ambrosino P; Iannuzzo G; Di Minno MND
J Am Heart Assoc; 2020 Aug; 9(15):e016262. PubMed ID: 32689862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
